Featured Articles

  1. Early Phase Oncology Site Network: Benefits Of A Personal Touch 11/17/2025

    Choose a site network built on partnership — not volume — to drive smoother early-phase oncology trials and deliver better outcomes for sponsors, sites, and patients.

  2. The Growing Complexity Of Conducting Oncology Trials 11/17/2025

    As diversity plans and multi-regional considerations become core to trial design, early-phase oncology programs must navigate a landscape that offers unprecedented opportunity.

  3. Precision Medicine: Targeted Cancer Therapies 10/2/2025

    Cancer research is entering a new precision-driven era, with targeted therapies focusing on the specific genetic or molecular mechanisms that fuel tumor growth.

  4. Specialized Site Network For Early-Phase Oncology Success 10/2/2025

    Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.

  5. Working With A Specialty Oncology CRO Versus A Large Generalist CRO 10/2/2025

    Specialty oncology CROs bridge the gap between traditional CRO operating models and the specialized needs of oncology sponsors by embedding deep oncology expertise across every function.

  6. Key Takeaways From ADCs In Oncology Trials Webinar 10/2/2025

    By aligning cutting-edge design with evolving regulatory expectations, sponsors can unlock the full therapeutic potential of ADCs and deliver transformative cancer treatments to patients worldwide.

  7. The Evolving Landscape Of Oncology Drug Development 9/17/2025

    Explore the novel drug modalities poised to revolutionize oncology and improve patient outcomes.

  8. The Resurgence Of Antibody-Drug Conjugates 9/1/2025

    As advancements in ADC technology and clinical trial methodologies progress, Antibody-Drug Conjugates (ADCs) are poised to become pivotal in precision oncology.

  9. Navigating Project Optimus And The Rapidly Changing Oncology Development Landscape 9/1/2025

    Project Optimus and adaptive trial designs are reshaping oncology development, improving patient outcomes, and streamlining approval pathways.

  10. Advancing Ovarian Cancer Therapies: Clinical Research Trends, Challenges, And Proven Strategies 8/29/2025

    Ovarian cancer remains one of the deadliest gynecologic malignancies. Successful clinical trials in this space demand deep therapeutic expertise, operational agility, and global coordination.